Susquehanna International Group’s Verona Pharma VRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-264,100
| Closed | -$28.2M | – | 13733 |
|
|
2025
Q3 | $28.2M | Sell |
264,100
-704,700
| -73% | -$73.6M | ﹤0.01% | 1858 |
|
|
2025
Q2 | $91.6M | Buy |
968,800
+482,700
| +99% | +$35.7M | 0.01% | 803 |
|
|
2025
Q1 | $30.9M | Buy |
486,100
+355,100
| +271% | +$21.2M | 0.01% | 1364 |
|
|
2024
Q4 | $6.08M | Buy |
131,000
+9,800
| +8% | +$368K | ﹤0.01% | 3309 |
|
|
2024
Q3 | $3.49M | Sell |
121,200
-182,100
| -60% | -$4.48M | ﹤0.01% | 4269 |
|
|
2024
Q2 | $4.39M | Buy |
303,300
+272,300
| +878% | +$3.98M | ﹤0.01% | 3656 |
|
|
2024
Q1 | $499K | Buy |
31,000
+20,900
| +207% | +$361K | ﹤0.01% | 8519 |
|
|
2023
Q4 | $201K | Sell |
10,100
-1,100
| -10% | -$16.2K | ﹤0.01% | 10676 |
|
|
2023
Q3 | $183K | Sell |
11,200
-21,800
| -66% | -$420K | ﹤0.01% | 10327 |
|
|
2023
Q2 | $698K | Sell |
33,000
-3,100
| -9% | -$66.1K | ﹤0.01% | 7529 |
|
|
2023
Q1 | $725K | Sell |
36,100
-24,500
| -40% | -$529K | ﹤0.01% | 7637 |
|
|
2022
Q4 | $1.58M | Buy |
60,600
+44,900
| +286% | +$598K | ﹤0.01% | 5162 |
|
|
2022
Q3 | $160K | Buy |
+15,700
| New | +$132K | ﹤0.01% | 11151 |
|
|
2022
Q1 | – | Sell |
-26,700
| Closed | -$179K | – | 14069 |
|
|
2021
Q4 | $179K | Buy |
+26,700
| New | +$136K | ﹤0.01% | 11582 |
|
Other funds holding VRNA
Susquehanna International Group's VRNA Position: Q2 2025 in Review
Susquehanna International Group sold out of Verona Pharma (VRNA) in Q2 2025, closing a stake of 33,655 shares — an estimated $2.49M sold.
Susquehanna International Group first reported a position in VRNA in Q4 2019 and held it in 12 quarters. The position peaked at $5.17M in Q4 2024. 292 funds tracked by Wall St. Rank hold VRNA as of Q2 2025.
- Susquehanna International Group reported no remaining Verona Pharma position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 33,655 Verona Pharma shares in Q2 2025, an estimated $2.49M.
- Susquehanna International Group first reported a position in Verona Pharma in Q4 2019 and held it in 12 quarters.
- Susquehanna International Group's Verona Pharma position peaked at $5.17M in Q4 2024.
- 292 funds tracked by Wall St. Rank held Verona Pharma as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.